loteprednol etabonate ophthalmic suspension, 0.2%
ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. Loteprednol etabonate is a white to off-white powder.
ALREX Ophthalmic Suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Published Studies Related to Alrex (Loteprednol Ophthalmic)
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. [2008.01]
PURPOSE: To compare the steroid-induced intraocular pressure (IOP) and other ocular adverse effects of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension with those of dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension... CONCLUSIONS: Loteprednol/tobramycin was significantly less likely to produce elevations in IOP than was dexamethasone/tobramycin in healthy subjects treated for 28 days. Both loteprednol etabonate/tobramycin and dexamethasone/tobramycin were well tolerated with low risks for systemic AEs and ocular AEs other than elevation in IOP for dexamethasone/tobramycin.
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. [2008.01]
CONCLUSIONS: LE/T satisfied the condition of non-inferiority to DM/T in decreasing the signs and symptoms of ocular inflammation associated with blepharokeratoconjunctivitis. Subjects treated with DM/T experienced more of an increase in IOP. Limitation: Although the single-masked design of this study could be considered a limitation, care was taken to ensure that the investigator was masked.
Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. [2007.01]
In this clinical trial, investigators compared the effectiveness of 2 commercially formulated antibiotic/steroid combinations - tobramycin 0.3%/dexamethasone 0.1% (Tobradex; Alcon, Fort Worth, Tex) and tobramycin 0.3%/loteprednol 0.5% (Zylet; Bausch & Lomb Inc., Rochester, NY) - for rapidly controlling inflammation in patients with blepharo-keratoconjunctivitis...
Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit. [2005.03]
BACKGROUND: Loteprednol etabonate (LE) is a novel soft steroid that was designed to improve the benefit/risk ratio of topical corticosteroid therapy. This study assesses the clinical efficacy and safety of three different doses of LE nasal spray in seasonal allergic rhinitis (SAR)... CONCLUSIONS: Loteprednol 400 microg once daily is superior to placebo and the only effective dose tested in improving nasal symptoms and objective parameters in patients with SAR.
A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. [2004.09]
PURPOSE: To evaluate loteprednol etabonate ophthalmic 0.5% suspension, versus placebo for treatment of the inflammatory component of keratoconjunctivitis sicca in patients with delayed tear clearance. DESIGN: Randomized, double-masked, placebo-controlled clinical trial... CONCLUSION: The use of topical loteprednol etabonate 0.5% 4 times a day may be beneficial in patients who have keratoconjunctivitis sicca with at least a moderate inflammatory component.
Clinical Trials Related to Alrex (Loteprednol Ophthalmic)
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis [Not yet recruiting]
Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically,
patients manifest symptoms in the spring, summer and fall, when airborne allergens are at
their peak. Patients may also be afflicted year-round, if sensitive to allergens such as
dust mites or pet dander. Signs and symptoms of allergic conjunctivitis are conjunctival
hyperemia, ocular itching, conjunctival and eyelid edema, papillary hypertrophy, tearing and
This is a randomized clinical study to evaluate the efficacy of Bepreve® (bepotastine
besilate 1. 5% ophthalmic solution) compared to Alrex® (loteprednol etabonate 0. 2%) in the
treatment of moderate to severe allergic conjunctivitis in patient over the age of 18 years.
The study wil lbe a two-week study with four visits. Ocular signs (eye redness( and
symptoms (itching) wil lbe omnotored as outcome variables.
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis [Recruiting]
This is a Phase IV, single site, randomized, double masked, parallel control clinical trial
of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for
treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy
will be measured by in-vivo confocal microscopy, corneal fluorescein staining, grading of
meibomian gland dysfunction and validated ocular symptom assessment questionnaire.
Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery [Recruiting]
Investigate the intraocular pressure(pressure inside the eye) of patients who are treated
with Lotemax after undergoing cataract surgery.
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye [Completed]
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group,
4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects
were randomized to receive loteprednol etabonate ophthalmic suspension, 0. 5% or placebo
(vehicle of loteprednol etabonate ophthalmic suspension, 0. 5%) and instructed to dose
bilaterally either TID or QID according to randomization.
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% [Recruiting]
Reports of Suspected Alrex (Loteprednol Ophthalmic) Side Effects
Eye Irritation (2),
Drug Hypersensitivity (2),
Condition Aggravated (2),
Lacrimation Increased (2),
Drug Ineffective (1),
Drug Ineffective FOR Unapproved Indication (1),
Vitreous Floaters (1),
Eye Pruritus (1),
Swelling Face (1),
Rash Generalised (1), more >>
Page last updated: 2008-03-26